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Purpose: Since several studies have proposed that epithe-
lial ovarian cancer should not be considered as a single 
disease entity and that it results from an accumulation of 
genetic changes, we aimed to assess the polymorphic expres-
sion of major cytosolic glutathione S-transferases (GSTM1, 
T1, A1 and P1) with respect to ovarian cancer susceptibility 
and aggressiveness. 
Methods: This case-control study was conducted on 93 
newly diagnosed epithelial ovarian cancer patients and 178 
healthy matched controls. The multiplex polymerase chain 
reaction (PCR) was used to detect homozygous deletions 
of GSTM1 and GSTT1 genes. Analysis of the single nucleo-
tide polymorphism (SNP) GSTA1 C69T was performed us-
ing PCR-restriction fragment length polymorphism (RFLP), 
while for SNP GSTP1 Ile105Val real-time PCR was used.
Results: No significant association to ovarian cancer risk 
was found for individual GSTM1, GSTA1 and GSTP1 
genotypes (p>0.05). However, the carriers of GSTT1-active 
genotype were at 2-fold higher risk of ovarian cancer devel-
opment (95%CI: 1.00-4.01, p=0.049), which was even more 
elevated in the subgroup of patients with positive family 
history of cancer. Moreover, the frequency of all three GST 
genotypes that might be associated to ovarian cancer risk 
(GSTT1-active, GSTA1-active and GSTP1-referent) was 
significantly higher in patients than in the control group 
(p=0.042). Even more, patients who were carriers of combi-
nation of these three genotypes represented over 64% of the 
total number of patients within any of the International 
Federation of Gynecology and Obstetrics (FIGO) stages of 
ovarian cancer.
Conclusions: This study provides supportive evidence that 
GSTs might affect both susceptibility and progression of 
ovarian cancer.
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Ovarian cancer is the seventh most common 
cancer in women worldwide and accounts for 
nearly 4% of all new cancer cases in females [1,2]. 
Its high death rate is due to the fact that approx-
imately 60% of women are diagnosed at an ad-
vanced stage of the disease [3]. Maximal surgical 
cytoreduction followed by chemotherapy, with 
initial response rate of 65-80% to first-line che-
motherapy, is considered gold standard for these 
patients [4,5]. Still, in most cases, the disease re-
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lapses and patients acquire resistance to further 
chemotherapy, leading to 5-year survival rate of 
30-50% [3,6]. 
Although, over the past decade, attempts have 
been made to develop more effective surgical 
techniques, as well as chemotherapy with combi-
nations of cytotoxic drugs, the overall cure rate 
for ovarian cancer remains approximately 30% 
[7]. Since ovarian cancer is thought to result from 
an accumulation of genetic changes [8], it is be-
lieved that significant changes in long-term sur-
vival in patients with ovarian cancer might only 
be achieved by personalized individual treatment 
strategies, as well as early detection of the disease 
[7]. For that reason, identification of inter-individ-
ual genetic variations, especially in genes encod-
ing enzymes involved in detoxification of antican-
cer drugs, seems reasonable.
Glutathione S-transferases (GSTs) are a large 
family of enzymes responsible for catalyzing the 
conjugation of xenobiotics, including anticancer 
drugs with glutathione [9]. Great inter-individual 
differences exist in GST isoenzyme profile, due to 
the fact that almost all members of seven class-
es of cytosolic GSTs exibit genetic polymorphism 
[9]. As a consequence, complete lack or alteration 
in GST enzyme activity might affect the capacity 
for biotransformation in certain individuals, mak-
ing them more prone to cancer development. 
In ovarian cancer, the cytosolic classes M1, 
T1 and P1 gained most attention as potential risk 
determinants [10–13], while GSTA1 class, which 
affects cellular redox balance, has not been evalu-
ated in ovarian cancer as yet. 
Apart from the well established role of GSTs 
in the susceptibility to cancer, they might also af-
fect chemotherapy response. Sawers et al. quite 
recently demonstrated that GSTP1 has an import-
ant role in cisplatin and carboplatin metabolism 
in ovarian cancer cells and that inter-tumor dif-
ferences in GSTP1 expression directly influence 
response to platinum-based chemotherapy in 
ovarian cancer patients [14]. These results imply 
that identification of subgroups of patients with 
ovarian cancer who might benefit from novel 
first-line therapies, based on their detoxification 
capacity and the ability to maximize benefits and 
minimize toxicity of applied antitumor drugs, is 
of high importance.
For that reason, in this study, polymorphic ex-
pression of major cytosolic GST classes, M1, T1, 
A1 and P1 were analyzed with respect to ovarian 
cancer susceptibility. Furthermore, the association 
with ovarian cancer aggressiveness was assessed. 
Methods
Study population
This case-control study was conducted on 93 
newly diagnosed epithelial ovarian cancer patients 
(all Caucasian, mean age 59.34 ± 11.22) treated at the 
Clinic of Gynecology University Teaching Hospital Ze-
mun-Belgrade, Institute of Oncology Clinical Center of 
Serbia and Oncology Institute of Vojvodina between 
May 2014 and October 2015. Ovarian cancer (serous, 
endometrioid, mucinous and clear-cell) was diagnosed 
according to the criteria of the World Health Organi-
zation classification of tumors of female reproductive 
organs [15] and staged according to the International 
Federation of Gynecology and Obstetrics (FIGO) stag-
ing classification [16]. Response rate was 92% and the 
most common reason for patients not to participate in 
the study was personal. The control group comprised 
178 women (all Caucasian, mean age 60.65 ± 12.40) 
who had undergone surgery for benign conditions. Se-
lection criteria for control individuals were no evidence 
of any personal or family history of ovarian cancer. The 
basic demographic data and assumed risk factors for 
ovarian cancer were obtained from the study subjects 
using a structured questionnaire composed at the In-
stitute of Epidemiology, Faculty of Medicine Universi-
ty in Belgrade, during the time of blood collection. In 
our study, obese patients were defined as individuals 
with body mass index (BMI) above 25 and smokers as 
individuals who reported every day smoking for a min-
imum of 60-day period prior to their enrollment in the 
study. Furthermore, participants were asked about the 
number of cigarettes smoked per day and duration of 
smoking. All collected data referred to a time period 
prior to the diagnosis of ovarian cancer for the cases, 
and a corresponding period for the controls. The study 
was approved by the Ethics Board of the Faculty of 
Medicine, University of Belgrade, Serbia, and was per-
formed in accordance with principles of Helsinki decla-
ration. Written informed consent was obtained from all 
recruited subjects.
DNA isolation and GST genotyping
Genomic DNA was isolated from whole peripheral 
blood, using DNA kit (Qiagen, Chatsworth CA, USA). 
DNA concentration was measured on GeneQuant pro 
(Biochrom, Cambridge, England). 
The multiplex PCR was used according to the 
method by Abdel-Rahman et al. [17] to detect gene dele-
tion polymorphism of GSTM1 and GSTT1 genes.  Apart 
from primers used for GSTM1 (forward 5′-GAACTC-
CCTGAAAAGCTAAAGC-3′ and reverse 5′-GTTGGGCT-
CAAATATACGGTGG-3′) and GSTT1 (forward 5′-TTCCT-
TACTGGTCCTCACATCTC-3′ and reverse 5′-TCACCGGAT-
CATGGCCAGCA-3′), the method included primers for the 
CYP1A1 (forward 5’-GAACTGCCACTTCAGCTGTCT-3’ 
and reverse 5’-CAGCTGCATTTGGAAGTGCTC-3’) house-
keeping gene that served as an internal control for am-
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plifiable DNA. The PCR protocol started with the de-
naturation at 94ºC for 4 min, followed by 94ºC for 30 
s, annealing at 59ºC for 30 s, extension at 72ºC for 45 
s (#cycles: 30), with final extension at 72ºC for 5 min. 
This method detects the presence (at least one allele 
present, homozygote or heterozygote) or absence (com-
plete deletion of both alleles, homozygote) of genotype. 
Analysis of the SNP GSTA1 C69T (rs3957356) 
was performed using PCR-RFLP, using GSTA1 prim-
ers (forward 5′-GCATCAGCTTGCCCTTCA -3′ and re-
verse 5′-AAACGCTGTCACCGTCCTG-3′) with Eam1104I 
(Thermo Fisher Scientific, Massachusetts, USA) restric-
tion enzyme, according to the method by Ping et al. 
[18]. The PCR protocol included denaturation at 94ºC (4 
min), followed by 94ºC for 20 s, annealing at 58ºC for 20 
s and extension at 72ºC for 40 s (#cycles: 33) with final 
extension at 72ºC for 5 min.
For analyses of SNP GSTP1 Ile105Val (rs1695), re-
al-time PCR allelic discrimination was performed on 
Mastercyclerep realplex (Eppendorf, Hamburg, Germa-
ny) using Applied BiosystemsTaqMan® Drug Metabo-
lism Genotyping assay according to the manufacturer’s 
instructions (Life Technologies, Applied Biosystems, 
Carlsbad, CA, USA, assay ID C_3237198_20). 
Researchers that performed genotyping were un-
aware of the case-control status, and blinded quality 
control samples were inserted to validate genotyping 
identification procedures. Concordance for blinded 
samples was 100%.
Statistics
Statistical analyses were performed using the Sta-
tistical Package for Social Sciences software (IBM Sta-
tistics SPSS, version 20.0). In descriptive statistics con-
tinuous variables were summarized by mean ± stan-
dard deviation (x±SD) or median with min-max values. 
Relative associations between the studied genotypes 
and ovarian cancer risk were evaluated by multino-
mial logistic regression to calculate odds ratios (OR) 
and 95% confidence intervals (CI). Differences in inves-
tigated parameters were assessed by using Student’s 
t-test for continuous data with normal distribution and 
Mann–Whitney rank-sum test for continuous data with 
non-normal distribution. Finally, x2 test was used for 
categorical variables. A p value of ≤ 0.05 was consid-
ered as statistically significant. 
Results
Patients with epithelial ovarian cancer and 
respective controls did not differ in terms of age, 
obesity and smoking (p>0.05). Namely, the mean 
BMI in patients was 25.94 ± 4.42 in comparison 
to 26.26 ± 5.01 in the control group (p=0.611). Re-
garding smoking, median pack-years was 15.75 in 
the patient group compared to 20 in the control 
group (p=0.382) (data not shown). All other base-
line demographic characteristics of patients with 
ovarian cancer are shown in Table 1. The major-
ity of patients had 2 births (52%), endometriosis 
was diagnosed in only 5 patients (5%), while only 
3 patients (3%) were under hormone treatment. 
Fourteen patients (15%) had positive family his-
tory of cancer (either ovarian or breast cancer), 
while, interestingly, one patient had two closest 
relatives with ovarian and breast cancer (Table 1). 
When stratified according to FIGO staging classi-
fication, 35 patients (38%) had FIGO I, 23 (24%) 
FIGO II and the remaining 38% FIGO III.
Table 1. Baseline demographic characteristics of 
patients with ovarian cancer 
Characteristics Patients, N (%)
Age (years), mean ±SD 59.34 ± 11.22
Obesity
BMI < 25 44 (48)
BMI > 25 49 (52)
BMI (kg/m2), mean ±SD 25.94 ± 4.42
Smoking 
Never 55 (59)
Ever1 38 (41)
Pack-years, median (range)1 15.75 (0.30 - 66.00)
Number of births
0 13 (14)
1 24 (26)
2 48 (52)
3 7 (7)
4 1 (1)
Endometriosis
No 88 (95)
Yes 5 (5)
Family history of cancer
No 79 (85)
Yes 14 (15)2
Ovarian cancer 6 (6)
Breast cancer 9 (10) 
Ever user of hormones
No 90 (97)
Yes 3 (3)
FIGO stage
I 35 (38)
II 23 (24)
III  35 (38)
1At least 60 cigarettes smoked prior to the study onset. 2One pa-
tient had two closest relatives with ovarian and breast cancer. 
BMI: body mass index, FIGO: International Federation of Gyne-
cology and Obstetrics staging classification
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GST genotypes and ovarian cancer risk
The distribution of GST genotypes in ovarian 
cancer patients is presented in Table 2. No sig-
nificant association with ovarian cancer risk was 
found for GSTM1 genotype (OR=0.93, 95%CI: 0.55-
1.59, p=0.811). On the other hand, the frequency 
of GSTT1-active genotype was higher in patients 
with ovarian cancer than in controls and these 
individuals were at 2-fold higher risk of ovarian 
cancer development (95%CI:1.00-4.01, p=0.049). 
Results obtained on the GSTA1 C69T (rs3957356) 
SNP polymorphism showed that carriers of at least 
one GSTA1-active allele were more frequent in the 
patient group, however without statistical signif-
icance (p=0.162). Similar results were found with 
Table 2. GST genotypes in relation to the risk of ovarian cancer
GST genotype PatientsN (%)
Controls
N (%) OR (95%CI)
7 p value
GSTM1
Active1 44 (52) 89 (50) 1.00 (reference group)
Null2 41 (48) 89 (50) 0.93 (0.55-1.59) 0.811
GSTT1
Null2 13 (15) 47 (26) 1.00 (reference group)
Active1 72 (85) 131 (74) 2.00 (1.00-4.01) 0.049
GSTA1 (rs 3957356)
CC+CT (active)3 80 (92) 151 (85) 1.00 (reference group)
TT (low activity)4 7 (8) 27 (15) 0.52 (0.22-1.23) 0.162
GSTP1 (rs1695)
IleIle+IleVal (referent)5 78 (92) 150 (84) 1.00 (reference group)
ValVal (variant)6 7 (8) 28 (16) 0.53 (0.21-1.31) 0.169
1if at least one active allele present; 2if no active alleles present; 3if at least one C allele present; 4Low activity, if both T alleles present; 
5Referent, if at least one Ile allele present; 6Variant, if both Val alleles present; 7Odds ratio adjusted to age, BMI and pack-years; CI: con-
fidence interval; GSTM1 and GSTT1 genotyping was successful in 85 cases and all recruited controls; GSTA1 C69T and GSTP1 Ile105Val 
genotyping was successful in 87 and 85 ovarian cancer cases, respectively, and all recruited controls
Table 3. GST genotypes in relation to the risk of ovarian cancer in patients with family history of cancer
GST genotype PatientsN (%)
Controls
N (%) OR (95%CI)
7 p value
GSTM1
 Active1 6 (46) 89 (50) 1.00 (reference group)
 Null2 7 (54) 89 (50) 1.35 (0.41-4.33) 0.620
GSTT1
 Null2 1 (7) 47 (26) 1.00 (reference group)
 Active1 13 (93) 131 (74) 5.17 (0.64-41.66) 0.123
GSTA1 (rs 3957356)
 CC+CT (active)3 11 (85) 151 (85) 1.00 (reference group)
 TT (low activity)4 2 (15) 27 (15) 0.82 (0.25-6.38) 0.769
GSTP1 (rs1695)
 IleIle+IleVal (referent)5 10 (83) 150 (84) 1.00 (reference group)
 ValVal (variant)6 2 (17) 28 (16) 0.79 (0.23-6.01) 0.843
1if at least one active allele present; 2if no active alleles present; 3if at least one C allele present; 4if both T alleles present; 5if at least one 
Ile allele present; 6Variant, if both Val alleles present; 7Odds ratio adjusted to age, BMI and pack-years; CI: confidence interval 
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respect to GSTP1 Ile105Val (rs1695) SNP poly-
morphism. Namely, the frequency of GSTP1-refer-
ent genotype was higher, while the frequency of 
GSTP- variant genotype was lower in patients with 
ovarian cancer in comparison to controls (OR=0.53, 
95%CI: 0.21-1.31, p=0.169).
Analysis of GST genotypes with regard to the 
risk of ovarian cancer in patients with family his-
tory of cancer further confirmed the results ob-
tained on the whole study group, especially with 
respect to GSTT1 genotype (Table 3). Namely, pa-
tients with familial history of ovarian or breast 
cancer, who were carriers of GSTT1-active geno-
type were at 5.17-fold increased risk of getting 
ovarian cancer, however without statistical signif-
icance (p=0.123), possibly due to the small sample 
size.
Combined effect of GST genotypes on ovarian cancer 
risk
Statistical analysis of the combined effect of 
GST genotypes on ovarian cancer risk showed no 
significant association for any of GSTM1, GSTT1, 
GSTA1 and GSTP1 genotypes. Still, it seems that 
genotypes that might be associated to ovari-
an cancer risk (GSTT1-active, GSTA1-active and 
GSTP1-referent) were more frequent in patients 
than in controls in any of the examined combi-
nations (Table 4). For that reason, the cumulative 
effect of suggested risk-associated GST genotypes 
was analyzed in patients with ovarian cancer in 
comparison to the control group (Table 5). Indeed, 
the results obtained showed that the combination 
of all three GST genotypes that might be associat-
ed to ovarian cancer risk (GSTT1-active, GSTA1- ac-
tive and GSTP1-referent) was present in 72% of the 
patients which was significantly higher (p=0.042) 
compared to the control group (54%).
Finally, the distribution of ovarian cancer pa-
tients with risk-associated genotypes (GSTT1-ac-
tive, GSTA1-active and GSTP1-referent) was ana-
lyzed within the total number of patients stratified 
according to FIGO classification. Interestingly, 
patients who were carriers of GSTT1-active/ GS-
TA1-active/GSTP1-referent genotype represented 
over 64 % of the total number of patients within 
any of FIGO stages of ovarian cancer (64, 78 and 
75% within FIGO I, FIGO II and FIGO III, respec-
tively) (Figure 1).
Discussion
To best of our knowledge, this is the first at-
tempt to study the association between the 4 most 
common GST polymorphisms and epithelial ovar-
ian cancer risk in Serbian women. Women with 
GSTT1-active genotype were at increased risk for 
ovarian cancer genesis in comparison to those 
with GSTT1-null genotype, which was even more 
evident in the subgroup of patients with positive 
family history of cancer. Moreover, the frequency 
of all 3 GST genotypes that might be associated 
to ovarian cancer risk (GSTT1-active, GSTA1-active 
and GSTP1-referent) was significantly higher in 
patients than in the control group. 
Table 4. Effects of combined GST genotypes in relation to the risk of ovarian cancer
GST genotype combination PatientsN (%)
Controls
N (%) OR (95%CI)
7 p value
GSTM1 and GSTT1
 GST-M11 active/GSTT1-null2 4 (5) 23 (13) 1.00 (reference group)
 GSTM1-null2/GSTT1-active1 32 (37) 65 (36) 2.92 (0.92-9.32) 0.069
GSTT1 and GSTA1
 GSTT1-null/GSTA1-low activity3 1 (1) 8 (5) 1.00 (reference group)
 GSTT1-active/GSTA1-active4 67 (78) 112 (63) 5.42 (0.66-44.59) 0.116
GSTT1 and GSTP1
 GSTT1-null/GSTP1-variant5 1 (1) 10 (6) 1.00 (reference group)
 GSTT1-active/GSTP1-referent6 64 (77) 113 (63) 6.11 (0.74-49.96) 0.091
GSTA1 and GSTP1
 GSTA1-low activity/GSTP1-variant 1 (1) 5 (3) 1.00 (reference group)
 GSTA1-active/GSTP1-referent 72 (85) 128 (72) 2.91 (0.31-2.71) 0.347
1Active, if at least one active allele present; 2Null if no active alleles present; 3Low activity, if both T alleles present; 4Active, if at least 
one C allele present; 5Variant, if both Val alleles present; 6Referent, if at least one Ile allele present; 7Odds ratio adjusted to age, BMI and 
pack-years. CI: confidence interval out of the total number of controls included in the study
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Over the years, many studies have attempted 
to elucidate triggering genetic factors in the de-
velopment of ovarian cancer, most of which were 
focused on the association between BRCA1, BRCA2 
and p53 genes and the ovarian cancer risk. Howev-
er, the frequencies of mutations in the mentioned 
genes were quite low [19,20]. Recently, several 
studies have shown that polymorphisms of GSTs 
could also affect the susceptibility to ovarian can-
cer due to their important role in the modulation 
of the biological effects of carcinogens. Special 
emphasis in this regard has been put on GSTM1 
and GSTT1 deletion polymorphisms, which, in 
carriers of GSTM1-null or GSTT1-null genotype, 
result in complete absence of active enzyme and 
thus reduce the cell’s ability to metabolize toxins 
[9]. However, the obtained results over the con-
tribution of these GSTs polymorphism to ovari-
an cancer risk are rather inconsistent [11,21–23] 
Moreover, the data from several meta-analyses do 
not provide a strong evidence for causal associa-
tions between GSTM1 and GSTT1 polymorphisms 
and risk of ovarian cancer in Caucasians [11,21-
23]. Our results with lack of significant contribu-
tion of GSTM1 gene polymorphism to the risk of 
ovarian cancer are in concordance with the afore-
mentioned studies [11,21-23]. 
On the other hand, the present study found 
increased risk to ovarian cancer in carriers of 
GSTT1-active genotype. This result might sound 
contradictory, having in mind that several en-
vironmental carcinogens found in combustion 
products and tobacco smoke, such as halogenated 
solvents, are among GSTT1 substrates [9]. How-
ever, there is strong evidence that GSTT1 enzyme 
might also be involved in bioactivation, rather 
than detoxification of several bifunctional alkylat-
ing agents, present in environmental pollution 
and certain occupational hazards [24]. As a con-
sequence, bioactivation process can yield potent 
electrophiles that modify DNA and are potential-
ly genotoxic [24,25]. Therefore, our results are in 
concordance with the study of Sgambato et al. 
who showed that GSTT1-null genotype is associ-
ated with decreased risk of cancer [26]. 
GSTP1 SNP (rs1695), resulting from ami-
no acid substitution from isoleucine (Ile) to va-
line (Val) [9], can affect both its catalytic and 
non-catalytic activity [27]. Although the car-
riers of GSTP1*Ile105genotype have a higher 
catalytic efficiency for standard GST substrate 
(1-chloro-2,4-dinitrobenzene) than the *Val105 
variant [9], the latter seems to confer higher cat-
alytic efficiency in detoxification of polycyclic ar-
omatic hydrocarbon (PAH) diol epoxide, present 
in tobacco smoke [28]. GSTP1 also participates in 
the regulation of stress signaling and apoptosis 
via its non-catalytic activity [29]. Namely, it has 
been shown that the presence of specific GSTP1 
polymorphic variant can influence the degree of 
interaction between GSTP1 and c-Jun N-terminal 
kinase (JNK), proapoptotic member of mitogen-ac-
tivated protein kinase (MAPK) signaling pathway. 
In that way, the substitution of amino acid isole-
ucine (Ile) with valine (Val) at position 105 can 
alter GSTP1-mediated inhibitory effect of JNK ac-
tivity. Based on our results on increased ovarian 
cancer risk in GSTP1*Ile (referent) allele carriers, it 
might be speculated that the stronger GSTP1:JNK 
interaction could prevent activation of apoptosis in 
these women, further affecting the progression of 
disease. In addition, our data on 6-fold increased 
ovarian cancer risk in women carriers of combined 
“risk” genotypes (GSTT1-active/GSTP1*Ile) suggest 
Table 5. Risk-associated GST genotypes in ovarian cancer patients
Risk-associated GST  
genotypes1, N (%)
Patients with ovarian cancer  
N (%)
Controls, 
N (%)
0 0 2 (1)
1 3 (4) 17 (10)
2 20 (24) 62 (35)
3 60 (72) 97 (54)
p = 0.042
 1GSTT1-active and/or GSTA1-active and/or GSTP1-referent
Figure 1. Distribution of patients with risk-associated 
genotypes (GSTT1-active, GSTA1-active and GSTP1-refer-
ent) within the total number of patients stratified accord-
ing to FIGO classification.
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a high probability of their synergetic risk effect on 
carcinogenesis in these women. 
The role of GSTA1 polymorphism in ovarian 
cancer risk assessment has not been investigated 
as yet. This polymorphism is represented by three 
linked SNPs, resulting in differential expression 
with lower transcriptional activation of the vari-
ant GSTA1*B than the common GSTA1*A allele [9]. 
Although we did not find a significant individual 
association between GSTA1 polymorphism and 
ovarian cancer risk, surprisingly, it was a part of 
the suggested “risk associated GST combination” 
(GSTT1-active, GSTA1-active and GSTP1-referent), 
which was present in 72% of all patients. What is 
more, patients carriers of this combination repre-
sented over 64% of the total number of patients 
within any of FIGO stages, implying increased 
susceptibility to chemical-induced carcinogenesis 
in these individuals. Thus, it might be speculat-
ed that variations in the expression of GSTs due 
to genetic polymorphisms probably modulate the 
process of carcinogenesis and in that way contrib-
ute to the individual disease susceptibility. 
In addition to their influence on ovarian can-
cer risk, it is important to note that GST poly-
morphisms also can affect both the prognosis 
and the efficacy of chemotherapy in ovarian can-
cer patients. Namely, Khrunin et al. showed that 
GSTP1* Ile105Val polymorphism was strongly 
associated with progression-free survival [30]. 
Moreover, it has been shown that GSTP1*B allele 
is also involved in the development of drug resis-
tance [9] and as suggested in the study of Ghalia 
et al., GSTP1 levels may be useful for monitor-
ing during chemotherapy [31]. In this field there 
are recent data on the beneficial effect of Hsp90 
inhibitors in reversing cisplatin resistance of hu-
man ovarian cancer cell line (SKOV3), which was 
mediated by modifying the expression of multiple 
drug resistance related genes, especially GSTP1, 
p53, bcl-2, survivin, BRCA1 and BRCA2 [32]. 
Some limitations to the present study should 
be addressed. First of all, for case–control studies, 
the selection bias is unavoidable. Furthermore, 
the statistical power of this study is limited due 
to the relatively small sample size, which is a 
consequence of inclusion criteria that only pa-
tients with epithelial ovarian cancer were includ-
ed. However, despite the mentioned limitations, 
this study provides supportive evidence that GSTs 
might affect both susceptibility and progression 
of ovarian cancer. 
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